Chronic Lowering of Blood Pressure by Carotid Baroreflex Activation
Mechanisms and Potential for Hypertension Therapy

Thomas E. Lohmeier, Radu Iliescu

Abstract—Recent technical advances have renewed interest in device-based therapy for the treatment of drug-resistant hypertension. Findings from recent clinical trials regarding the efficacy of electric stimulation of the carotid sinus for the treatment of resistant hypertension are reviewed here. The main goal of this article, however, is to summarize the preclinical studies that have provided insight into the mechanisms that account for the chronic blood pressure–lowering effects of carotid baroreflex activation. Some of the mechanisms identified were predictable and confirmed by experimentation. Others have been surprising and controversial, and resolution will require further investigation. Although feasibility studies have been promising, firm conclusions regarding the value of this device-based therapy for the treatment of resistant hypertension awaits the results of current multicenter trials. (Hypertension. 2011;57:880-886.) ● Online Data Supplement

During the decade of the 1960s, various medical devices for electrically activating the carotid baroreflex were designed and used with the intent of lowering arterial pressure in patients whose severe hypertension was inadequately controlled by available medication.1–3 Although the findings in some early studies suggested that long-term stimulation of the carotid baroreflex might chronically lower arterial pressure, this approach for treatment of drug-resistant hypertension was abandoned for 2 primary reasons. The technology was too crude to achieve reliable baroreflex activation and long-term blood pressure responses, particularly without adverse effects. Moreover, the advent of new, effective pharmacological therapy for the treatment of hypertension diminished interest in further developing this invasive device-based therapeutic strategy for lowering blood pressure.

Since these studies almost 50 years ago, several different classes of drugs have been developed to treat hypertension. Given the success of drug therapy in treating hypertension and reducing associated adverse cardiovascular effects, it would appear paradoxical that there are now ongoing clinical trials evaluating the efficacy of this nonpharmacological approach for lowering arterial pressure. Why the recent interest in device-based therapy for the treatment of hypertension? There are 2 notable reasons for the resurgence of efforts directed at carotid baroreflex activation as a therapeutic strategy for the control of hypertension. First, despite the vast armamentarium of antihypertensive agents available to clinicians for treating hypertension, the percentage of patients achieving adequate blood pressure control remains unacceptably low.4 In some cases, patients would benefit from drug therapy optimization and better compliance. However, in some patients, adequate blood pressure control is not correctable by these approaches. These patients have resistant hypertension, defined as blood pressure that remains above goal in spite of the concurrent use of ≥3 antihypertensive agents, with 1 being a diuretic and all being given at an optimized dose.4,5 Despite thoughtful therapy, patients remain resistant to medical therapy and could benefit from new approaches, such as baroreflex stimulation. Another major impetus for current clinical trials using baroreflex therapy has been the development of modern device technology for baroreflex activation that has overcome the technical limitations encountered in the early studies using chronic carotid baroreflex activation.

The development of device-based therapy for activation of the baroreflex requires mechanistic knowledge of the role of the baroreflex in long-term control of arterial pressure. Preclinical studies in dogs subjected to chronic electric stimulation of the carotid sinus have provided insight into the basic physiological mechanisms that account for the sustained reductions in arterial pressure during prolonged activation of the baroreflex, and these studies are emphasized in this review. However, it will be apparent that a complete understanding of the blood pressure–lowering mechanisms still remains enigmatic. Some of the results have confirmed expected beliefs and predicted mechanisms, whereas others have been surprising and controversial. Finally, responses to carotid baroreflex activation in human subjects with resistant hypertension were variable and sometimes unpredictable.6,7 The variability was at least partially related to the degree of carotid sinus denervation,6 which was documented by electrophysiological methods in a subset of patients.

...
hypertension will be presented, including recently published findings from a recent feasibility trial demonstrating the safety and therapeutic efficacy of carotid sinus stimulation.

**Modern Features of Device-Based Carotid Baroreflex Activation**

Issues related to the technology and approach for chronic electric activation of the carotid baroreflex have been discussed in greater detail in earlier communications.5,6 With the present system for activation of the carotid baroreflex, the stimulating electrodes are implanted in the perivascular space around the carotid sinuses and not around the carotid sinus nerve, as in some of the early studies. Although not rigorously evaluated, this virtually eliminates the possibility of damage to the carotid sinus nerve, not an uncommon occurrence in studies conducted in the 1960s. Theoretically, stimulation of the carotid sinus also reduces the likelihood of activating carotid body chemoreceptor afferents, which, along with the baroreceptor fibers, are present in the carotid sinus nerve. This is important because activation of carotid body afferent fibers increases sympathetic activity and respiratory rate, undesirable responses that would limit the therapeutic efficacy of baroreflex activation. Additionally, problems reported in early studies related to extraneous nerve and muscle stimulation and pain have been solved using modern electrode technologies that permit localized electric stimulation of carotid baroreceptors. Another important feature is that the internally implantable, miniature pulse generator is completely programmable by radiofrequency control using an external programming system similar in concept to that used for cardiac pacemakers. This provides permanent control of current delivery along the leads to the electrodes and allows time-dependent modification of stimulation parameters. However, at present, more information is needed on the selection of optimal stimulation patterns and stimulation parameters. The ability of this system to be programmed for different current delivery throughout the day and night offers the intriguing possibility of customizing therapy to the particular day-night blood pressure pattern of the individual. To date, however, this application has not been tested. Finally, the associated rapid on- and off-transient arterial pressure responses and the potential to achieve graded and controllable long-term reductions in arterial pressure are additional desirable features of this device.

**Chronic Electric Activation of the Carotid Baroreflex Produces Sustained Reductions in Sympathetic Activity and Arterial Pressure**

A potential role of baroreflexes in long-term control of arterial pressure is often conceptually dismissed because of the accepted fact that baroreflexes reset in the direction of change in arterial pressure.7-10 Resetting diminishes the ability of the baroreflex to chronically alter sympathetic activity and, thus, serve as a long-term controller of arterial pressure. Resetting of the baroreflex arc occurs as a result of adaptations manifested centrally or at the baroreceptors themselves. Unfortunately, technical limitations have precluded a quantitative evaluation of the degree of baroreflex resetting in response to long-term changes in arterial pressure and the contribution of central adaptations to the resetting process. In regard to central resetting, if this were a dominant process that counteracts changes in baroreceptor input into the brain, then chronic electric activation of the carotid sinus would not be expected to produce appreciable, sustained reductions in sympathetic activity and arterial pressure. Clearly, this is not the case.

A unique aspect of the current technology for activation of the carotid baroreflex is that electric stimulation of the carotid sinuses bypasses mechanotransduction at the level of the baroreceptors and allows for precise control of carotid baroreceptor input into the brain. An especially important finding from experimental studies is that prolonged baroreflex activation leads to sustained reductions in arterial pressure and heart rate.6,11-15 Furthermore, the chronic lowering of blood pressure during baroreflex activation is associated with sustained reductions in plasma norepinephrine (NE) concentrations6,12-15 and whole-body NE spillover to plasma,15 indicating unremitting suppression of central sympathetic outflow. These responses indicate that central resetting is relatively unimportant in diminishing the suppression of sympathetic activity and the attendant reduction of blood pressure induced by prolonged electric activation of the carotid sinus. In addition, despite reduced arterial pressure, it would appear that the aortic baroreflex, constrained by resetting, also fails to increase sympathetic activity appreciably and offset the sympathoinhibition induced by stimulation of the carotid sinus. It is also relevant to point out that if the reactivity of $\alpha_1$-adrenergic receptors in the peripheral vasculature were to increase in response to reduced sympathetic outflow, this could counteract the fall in arterial pressure.16 However, experimental studies have shown that, despite the chronic suppression of sympathetic activity, increases in $\alpha_1$-adrenergic receptor reactivity in the peripheral circulation do not provide a significant compensatory opposition to the fall in arterial pressure induced by baroreflex activation.15 Thus, neither adaptations within the central nervous system nor in the peripheral circulation offset the long-term sympathoinhibitory blood pressure–lowering effects of electric stimulation of the carotid baroreflex.

**Role of the Kidneys in Mediating the Chronic Blood Pressure–Lowering Effects of Baroreflex Activation**

Long-term regulation of arterial pressure is closely linked to volume homeostasis through the renal body-fluid feedback mechanism.7-9,17 According to this concept, for a given level of sodium intake, long-term changes in arterial pressure cannot occur without alterations in renal excretory function. Therefore, although the baroreflex plays an important role in short-term regulation of arterial pressure by mediating changes in peripheral resistance, vascular capacity, and cardiac function, these autonomic responses, even if sustained chronically, would not be expected to produce long-term changes in arterial pressure unless accompanied by alterations in pressure natriuresis. More specifically, in the absence of an increase in renal excretory function, chronic activation of the baroreflex should lead to only a transient fall in arterial pressure. This is because the initial fall in arterial pressure...
that reductions in renal perfusion pressure studies in chronically instrumented dogs have demonstrated substantial reductions in arterial pressure.6,11–15 Quantitative titration is the failure of renin secretion to increase, despite A noteworthy observation during chronic baroreflex activation of Baroreflex Activation Resistant to the Blood Pressure–Lowering Effects Angiotensin II Hypertension Is Relatively

Angiotensin II Hypertension Is Relatively Resistant to the Blood Pressure–Lowering Effects of Baroreflex Activation

A noteworthy observation during chronic baroreflex activation is the failure of renin secretion to increase, despite substantial reductions in arterial pressure.6,11–15 Quantitative studies in chronically instrumented dogs have demonstrated that reductions in renal perfusion pressure ≥15 mm Hg lead to marked increases in renin secretion.22,23 Therefore, baroreflex activation must have an inhibitory influence on renin secretion, because sustained reductions in mean arterial pressure (MAP) of 20 to 25 mm Hg during carotid sinus stimulation do not increase plasma renin activity (PRA). Because alterations in renal adrenergic activity have both acute and chronic effects on renin secretion, it is likely that sustained reductions in RSNA account for the long-term inhibitory effects of baroreflex activation on renin secretion, an effect that counteracts pressure-dependent renin release. Based on this impressive inhibitory influence on renin secretion, we hypothesized that, were it not for the sustained renal sympathoinhibitory effects on renin secretion, the long-term blood pressure–lowering response to baroreflex activation would be greatly diminished.

This hypothesis was tested during equivalent degrees of carotid sinus stimulation before and during continuous infusion of angiotensin (Ang) II. Tests were performed in the same dogs at an infusion rate producing high physiological levels of the potent sodium-retaining hormone.11 Under control conditions before Ang II infusion, acute and chronic reductions in MAP (≥20 mm Hg) in response to baroreflex activation were comparable. Next, after induction of Ang II hypertension, the acute fall in MAP in response to baroreflex activation was found to be similar to that observed under control conditions. However, this robust hypotensive response did not persist during chronic baroreflex activation and concurrent infusion of Ang II (Figure). Compared with the response under control conditions, the chronic blood pressure–lowering effect of baroreflex activation was diminished by 75% to 80% in Ang II hypertension. This study clearly demonstrates that the long-term antihypertensive effects of baroreflex activation are markedly diminished in the presence of modest and persistent increases in circulating levels of Ang II and, therefore, emphasize the importance of reflex-mediated suppression of renin secretion in counteracting pressure-dependent renin release and permitting lowering of arterial pressure.

The preexisting level of RSNA may be another determinant of the long-term arterial pressure response to baroreflex activation and a contributing factor to the diminished antihypertensive response to electric stimulation of the carotid sinus in Ang II hypertension. Experimental studies in chronically instrumented animals have clearly demonstrated that naturally induced, baroreflex-mediated suppression of RSNA is a sustained response to Ang II hypertension.18–20 Thus, if RSNA is already suppressed in Ang II hypertension as a result of the natural engagement of the baroreflex, it would be reasonable to expect diminished inhibition of RSNA and arterial pressure during electric activation of the baroreflex. If this rationale is correct, the antihypertensive effects of baroreflex activation would be expected to be substantial in forms...
of hypertension associated with increased RSNA, such as obesity hypertension.

**Obesity Hypertension Is Totally Abolished by Baroreflex Activation**

There is considerable evidence that activation of the sympathethic nervous system plays an important role in the pathogenesis of obesity hypertension. Furthermore, increased RSNA is clearly implicated in the hypertensive process. Therefore, because chronic activation of the baroreflex has sustained effects to suppress RSNA, we hypothesized that electric stimulation of the baroreflex would greatly diminish the severity of hypertension in obese dogs fed a high-fat diet. After 4 weeks of feeding dogs a high-fat diet, MAP increased \( \approx 15 \text{ mm Hg} \) in association with a 50% increase in weight gain. Tachycardia and increased plasma levels of NE were prominent features associated with the hypertension, consistent with activation of the sympathetic nervous system. Baroreflex activation during week 5 of the high-fat diet greatly attenuated the tachycardia and totally abolished the increments in plasma NE concentration and arterial pressure associated with weight gain. There were no changes in PRA during prolonged stimulation of the carotid baroreflex. Thus, in contrast to the Ang II model of hypertension, the antihypertensive effects of baroreflex activation were pronounced and sustained in obesity hypertension (Figure). These findings suggest greater degrees of baroreflex-induced renal sympathoinhibition in obesity than in Ang II hypertension, with preexisting levels of RSNA being high in obesity and low in Ang II hypertension. Furthermore, as in normotensive dogs, the absence of an increase in PRA, despite the large fall in MAP, supports the hypothesis that reductions in RSNA counteract pressure-dependent renin secretion during baroreflex activation. Once again, had renal sympathoinhibition not offset pressure-dependent renin release, it is likely that the antinatriuretic effects of increased circulating Ang II would have diminished the antihypertensive response to baroreflex activation.

**Presence of the Renal Nerves Is Not an Obligate Requirement for Long-Term Reductions in Arterial Pressure During Baroreflex Activation**

The above studies, along with observations in hypertensive animals during natural activation of the baroreflex, indicate that the renal nerves provide a logical link between reductions in central sympathetic outflow and increased renal excretory function that leads to chronic lowering of blood pressure during prolonged activation of the baroreflex. Therefore, we directly evaluated the importance of the renal nerves in mediating long-term baroreflex-mediated reductions in arterial pressure by chronically activating the carotid baroreflex in the same normotensive dogs before and, after a recovery period, after bilateral renal denervation. We hypothesized that if the renal nerves are critical mediators of the long-term blood pressure–lowering effects of the baroreflex, then chronic electric stimulation of the carotid sinus would not lead to sustained reductions in arterial pressure after renal denervation. To our great surprise, the lowering of arterial pressure in response to activation of the baroreflex after renal denervation was not significantly different from when the renal nerves were intact, although there was a tendency for greater sodium retention and a smaller fall in arterial pressure in the absence than in the presence of the renal innervation. Therefore, we speculated that, after renal denervation, the sustained fall in arterial pressure during baroreflex activation depended on a greater degree of fluid retention and attendant, exaggerated activation of redundant natriuretic mechanisms. Although not tested experimentally, theoretical support for this hypothesis was provided from computer simulations using an established integrative mathematical model of human physiology (Quantitative Human Physiology, QHP2008). This model predicted that, after renal denervation, there is excessive fluid retention during baroreflex activation and that increased plasma levels of atrial natriuretic peptide and renal interstitial pressure become increasingly important in promoting sodium excretion and lowering arterial pressure.

**Baroreflex Activation Enhances Drug-Induced Lowering of Arterial Pressure in Experimental Studies**

As indicated above, an impetus for the development of technology for electric stimulation of the carotid sinus has been the need for new treatments for blood pressure control in patients with resistant hypertension. Because subjects with resistant hypertension have inadequate blood pressure control despite therapy involving multiple drug regimens, we evaluated whether baroreflex activation might potentiate the blood pressure–lowering effects of different classes of antihypertensive drugs. Clinical studies have shown that the chronic lowering of blood pressure associated with some drugs, including diuretics and calcium channel blockers, leads to chronic increases in sympathetic activity, which might be expected to attenuate antihypertensive efficacy.

Our previous studies in dogs suggested that prolonged baroreflex activation had the capacity to reduce arterial pressure considerably more than chronic blockade of \( \alpha_1 \)- and \( \beta_1,2 \)-adrenergic receptors. Therefore, we determined whether central inhibition of sympathetic outflow by baroreflex activation would lower arterial pressure by mechanisms distinct from diminished activation of the adrenergic receptors believed to be most important in mediating the actions of the sympathetic nervous system. During chronic administration of prazosin and propranolol, at doses that completely blocked the normal agonist stimulation of \( \alpha_1 \)- and \( \beta_1,2 \)-adrenergic receptors, MAP decreased \( \approx 20 \text{ mm Hg} \). However, this lowering of blood pressure during chronic adrenergic blockade was associated with sustained activation of the sympathetic nervous system, as reflected by a 3-fold increase in plasma NE concentration. The additional advantage of reflex-induced sympathoinhibition in lowering arterial pressure was apparent during the subsequent week of baroreflex activation and continued adrenergic blockade. During the 7 days of baroreflex activation, MAP fell by an additional 10 mm Hg, concomitant with reductions in plasma NE concentration to control levels. Although possibly hormonally mediated, the abrupt changes in arterial pressure immediately after baroreflex activation suggested that this additional long-term fall in arterial pressure was because of
reduced release of NE and/or cotransmitters from adrenergic nerve terminals. Based on the pronounced vasoactive responses to localized arterial administration of $\alpha_2$-adrenergic receptor antagonists in dogs and human subjects, we focused on the possibility that diminished NE release and attendant activation of postfunctional vasoconstrictor $\alpha_2$-adrenergic receptors contributed importantly to the additional blood pressure–lowering effects of baroreflex activation during $\alpha_1$-and $\beta_1$-adrenergic blockade. Indeed, in response to acute administration of a peripherally acting $\alpha_2$-antagonist, there was a considerably smaller fall in MAP during adrenergic blockade + baroreflex activation than during adrenergic blockade alone.

A similar scenario occurred during chronic administration of another commonly used antihypertensive agent, the calcium channel blocker amlodipine. As with adrenergic blockade, the chronic lowering of blood pressure during amlodipine administration (MAP decreased $\approx 15$ mm Hg) was associated with a sustained increase in sympathetic activity (plasma NE concentration). In parallel with activation of the sympathetic nervous system, PRA increased 6-fold. Moreover, with continued amlodipine administration, MAP continued to decrease by $> 10$ mm Hg during the subsequent 7 days of baroreflex activation. This additional reduction in arterial pressure during baroreflex-mediated suppression of central sympathetic outflow occurred concomitantly with the return of plasma NE concentration and PRA to or almost to control levels.

Taken together, these findings suggest that the fall in arterial pressure with some classes of antihypertensive drugs is associated with sustained activation of the sympathetic nervous system, presumably because of the natural unloading of arterial baroreceptors. Furthermore, they indicate that this reflex-induced sympathoexcitation attenuates the lowering of blood pressure and that concomitant inhibition of central sympathetic outflow by baroreflex activation lowers arterial pressure further. Thus, persistent baroreflex-mediated sympathetic activation during chronic antihypertensive therapy may be a mechanism contributing to resistant hypertension. Furthermore, the ability of carotid sinus stimulation to counteract drug-induced sympathetic activation by suppressing central sympathetic outflow may partially account for the lowering of arterial pressure in patients with resistant hypertension.

**Baroreflex Activation Therapy in Patients With Resistant Hypertension**

The first comprehensive evaluation of baroreflex activation therapy for resistant hypertension is now complete (please see the online Data Supplement at http://hyper.ahajournals.org for a listing of all CVRx-sponsored trials registered at www.clinicaltrials.gov). The Device-Based Therapy in Hypertension Trial (identifier NCT00710190) was a multicenter, prospective, nonrandomized feasibility trial evaluating the safety and efficacy of 3 months of baroreflex activation therapy in 45 patients with resistant hypertension. All of the subjects received optimal doses of antihypertensive medications, with the median number of drugs being 5. During this time, medications were kept constant for 2 months before entry and during the 3 months of therapy. Baseline arterial pressure and heart rate were 179/105 mm Hg and 80 bpm, respectively. After 3 months of continuous, bilateral device-based therapy, there was a statistically significant reduction in arterial pressure by 21/12 mm Hg and in heart rate by 8 bpm. Furthermore, in a cohort of subjects followed for 2 years of therapy, these results were sustained and possibly even improved. After 1 year of baroreflex activation (n = 26), reductions in arterial pressure and heart rate were 30/8 mm Hg and 8 bpm, respectively. The corresponding values after 2 years (n = 17) were 33/22 mm Hg and 11 bpm. There were no significant changes in the number of antihypertensive drugs taken by the patients during the 2-year time period. Optimal stimulation parameters were identified on an individual basis as part of the acute dose-response testing that occurs at follow-up, and all of the subjects were stimulated bilaterally. In contrast, the majority of patients enrolled in the Pivotal Trial (discussed next), have been programmed for unilateral activation.

Thus, in patients with resistant hypertension, chronic baroreflex activation decreased arterial pressure beyond what could be achieved with drug treatment. Furthermore, the procedure and device were well tolerated with favorable measures of safety during 2 years of therapy. With these encouraging results, a Food and Drug Administration approved randomized, double-blind, placebo-controlled US/European Pivotal Trial (identifier NCT00442286) has been ongoing since 2007. After all of the patients were fully enrolled and implanted (n = 326), the Data Safety Monitoring Board informed investigators that the 6-month efficacy endpoint was not likely to be met: the predetermined responder analysis comparing therapy and control groups underestimated the magnitude of pressure reduction observed in the control group. Results of patients through 1 year of therapy are strikingly consistent with results from the forerunner Device-Based Therapy Trial discussed above. Patients continue to be followed, and full trial results will be presented in 2011, after completion of all of the end point–related follow-up visits.

Greater insight into the physiological responses to baroreflex activation in patients with resistant hypertension has been provided by 2 studies in subgroups of patients from the Device-Based Therapy in Hypertension Trial. In one study, measurement of muscle sympathetic nerve activity by microneurography provided direct evidence for reduced muscle sympathetic nerve activity during acute baroreflex activation; in this study, acute depressor responses were correlated with reductions in muscle sympathetic nerve activity, suggesting a causal relationship. However, to date, chronic determinations of muscle sympathetic nerve activity in patients treated with baroreflex activation therapy are lacking. As afferent impulses during electric stimulation of the carotid sinus are continuous by design and not pulse synchronous, another important observation in this study was that baroreflex activation did not impair physiological baroreflex regulation. This observation is consistent with findings made during simultaneous 24-hour recordings of arterial pressure and heart rate in dogs. These recordings in dogs indicated that the sensitivity of spontaneous baroreflex control of heart rate
actually increased during chronic baroreflex activation, despite the pattern of continuous, nonpulsatile electric stimulation of the carotid sinus. Enhanced baroreflex sensitivity during continuous activation of the baroreflex may partially account for the absence of postural hypotension during device-based therapy in patients with resistant hypertension.34

Twenty-four–hour recordings of hemodynamics have provided further insight into dynamic baroreflex control of circulatory function during chronic electric stimulation of the carotid sinus. In a second subgroup of patients from the Device-Based Therapy in Hypertension Trial population, 24-hour recordings of ECGs showed increased heart rate variability, along with sustained reductions in arterial pressure and heart rate, when determined after 3 months of baroreflex activation therapy.36 Continuous hemodynamic measurements in dogs indicate that chronic baroreflex activation not only leads to increased heart rate variability but to decreased blood pressure variability as well.15 Taken together, these dynamic measures of circulatory function are consistent with inhibition of sympathetic activity and augmentation of parasympathetic activity during chronic electric stimulation of the baroreflex. By decreasing blood pressure variability and associated target organ damage37 and diminishing the likelihood of adverse cardiac events, these dynamic alterations in baroreflex function may contribute to the clinical benefit of baroreflex activation.

Conclusions

The experimental studies reviewed above have provided comprehensive insight into the mechanisms that account for the chronic lowering of blood pressure during suppression of central sympathetic outflow and, more specifically, during prolonged activation of the baroreflex. Although not directly tested, these studies suggest that baroreflex-mediated suppression of RSNA chronically increases renal excretory function and, in so doing, permits sodium balance during sustained reductions in arterial pressure. This increase in renal excretory function during baroreflex activation is critically dependent on diminished adrenergic stimulation of renin secretion, a response that offsets pressure-dependent renin release. However, there are clearly additional mechanisms beyond renal sympathoinhibition that promote sodium excretion during sustained activation of the baroreflex.

Older age, obesity, sleep apnea, and some classes of antihypertensive drugs are commonly associated with both increased sympathetic activity and resistant hypertension. Thus, increased sympathetic activity may have an unappreciated role in the pathogenesis of resistant hypertension. If this hypothesis is correct, it would account for the impressive antihypertensive responses to suppression of central sympathetic outflow by baroreflex activation in patients with resistant hypertension. Similarly, striking therapeutic blood pressure responses have also been reported in patients with resistant hypertension when subjected to a targeted approach for disrupting renal sympathetic drive to the kidneys, endovascular radiofrequency ablation of the renal sympathetic nerves.38 However, the therapeutic benefit of these devices in hypertension, and in other states of sympathetic activation such as heart failure,39 may also depend on their ability to not only suppress RSNA but sympathetic outflow to other regions as well.

It remains to be seen if and how rapidly baroreflex activation will be adopted in clinical practice. Various factors will influence this, including magnitude of pressure reduction, adverse outcome risk reduction, long-term safety profile, implant invasiveness, battery life, and lifetime treatment costs. As with device-based therapies in general, there will be an evolution of technology and evidence basis that will allow the healthcare system to determine the breath of appropriate indications.

Acknowledgments

We thank Eric Lovett for his helpful comments in reviewing this article.

Sources of Funding

The preclinical studies using electrical stimulation of the carotid sinus were supported by National Heart, Lung, and Blood Institute grant HL-51971 and CVRx, Inc.

Disclosures

T.E.L. has received consultant fees and is on the scientific advisory board of CVRx, Inc.

References

12. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, Kieval RS. Renal denervation does not abolish sustained


Chronic Lowering of Blood Pressure by Carotid Baroreflex Activation: Mechanisms and Potential for Hypertension Therapy
Thomas E. Lohmeier and Radu Iliescu

Hypertension. 2011;57:880-886; originally published online February 28, 2011;
doi: 10.1161/HYPERTENSIONAHA.108.119859
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/57/5/880

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2011/03/28/HYPERTENSIONAHA.108.119859.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/
ONLINE SUPPLEMENT

Chronic Lowering of Blood Pressure by Carotid Baroreflex Activation: Mechanisms and Potential for Hypertension Therapy

By

Thomas E. Lohmeier\textsuperscript{1} and Radu Iliescu\textsuperscript{1,2},
\textsuperscript{1}Department of Physiology, University of Mississippi Medical Center
Jackson, MS
and
\textsuperscript{2}Cardiovascular Research Department, “Gr. T. Popa” Center for Biomedical Research
and the University of Medicine and Pharmacy, “Gr. T. Popa”,
Iasi, Romania

Short Title: Carotid Sinus Stimulation and Blood Pressure

Corresponding Author:
Thomas E. Lohmeier, Ph.D.
Department of Physiology
University of Mississippi Medical Center
2500 North State St.
Jackson, MS 39216-4505
Ph: 601-984-1822
Fax: 601-984-1817
Em: tlohmeier@physiology.umc.edu
### Table S1. CVRx Clinical Trials

<table>
<thead>
<tr>
<th>ClinicalTrials.gov Identifier</th>
<th>Trial Name</th>
<th>Sample Size</th>
<th>Description</th>
<th>Primary Outcome Measures</th>
<th>Population</th>
<th>No. of Sites</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00710294</td>
<td>DEBuT - HET: Device Based Therapy in Hypertension Extension Trial: Long-Term Follow-Up Trial for Patients Who Completed the DEBuT-HT Study</td>
<td>45</td>
<td>A chronic, prospective, non-randomized, self-controlled registry of safety and blood pressure reduction efficacy in patients with refractory hypertension who in course of the DEBuT-HT trial have been implanted with the CVRx Rheos™ System for the electrical activation of the baroreflex.</td>
<td>Describe the safety of Rheos Baroreflex Hypertension Therapy System by evaluating all adverse events and estimating the system and procedure related adverse event rate until and including the 13-month follow-up.</td>
<td>Resistant hypertension defined as: Blood pressure greater than or equal to 160 mmHg systolic and/or greater than or equal to 90 mmHg diastolic despite two months of full therapy with at least three anti-hypertensive medications, of which at least one must be a diuretic.</td>
<td>9</td>
<td>Active, Not Recruiting</td>
</tr>
<tr>
<td>NCT01077180</td>
<td>Rheos Feasibility Trial</td>
<td>16</td>
<td>A clinical feasibility investigation designed to assess safety, device performance, and protocol parameters of the CVRx Rheos Baroreflex Hypertension Therapy System in patients with severe hypertension that are refractory to full drug therapy.</td>
<td>To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant). To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious system related event-free rate through 4 and 13 months post-implant.</td>
<td>Resistant hypertension defined as: Blood pressure greater than or equal to 160 mmHg systolic despite one month of full therapy with at least three anti-hypertensive medications, of which at least one must be a diuretic.</td>
<td>6</td>
<td>Completed</td>
</tr>
<tr>
<td>NCT00718939</td>
<td>Rheos Diastolic Heart Failure Trial</td>
<td>3</td>
<td>A prospecive trialto evaluate the safety and efficacy of the Rheos System in a Diastolic Heart Failure population.</td>
<td>To describe the effects of the Rheos Baroreflex Activation Therapy System on the left ventricular mass index (LVMI) at six months</td>
<td>Symptomatic Heart Failure with LVEF ≥ 45%, and cuff systolic blood pressure ≥140 mmHg</td>
<td>2</td>
<td>Active, Not Recruiting</td>
</tr>
<tr>
<td>NCT00710190</td>
<td>DEBuT-HT: Device Based Therapy in Hypertension Trial</td>
<td>45</td>
<td>A chronic, prospective, non-randomized, self-controlled registry of safety and blood pressure reduction efficacy in patients with refractory hypertension.</td>
<td>To demonstrate the safety and efficacy of the Rheos Baroreflex Hypertension Therapy System in patients with refractory hypertension.</td>
<td>Resistant hypertension defined as: Blood pressure greater than or equal to 160 mmHg systolic and/or greater than or equal to 90 mmHg diastolic despite two months of full therapy with at least three anti-hypertensive medications, of which at least one must be a diuretic.</td>
<td>9</td>
<td>Completed</td>
</tr>
<tr>
<td>NCT00957073</td>
<td>Health Outcomes Prospective Evaluation for Heart Failure With EF ≥ 40% (HOPE4HF)</td>
<td>540</td>
<td>The CVRx Health Outcomes Prospective Evaluation for Heart Failure with EF ≥ 40% (HOPE4HF) is a prospective, randomized trial. Subjects will be randomized in a 2:1 ratio to receive a Rheos system plus medical management (Device Arm) or to receive medical management alone (Medical Management Arm). The trial will utilize a phased enrollment process. Phase I of the study will be limited to 30 subjects randomized (20 implanted) at up to 10 U.S. sites.</td>
<td>1. Cardiovascular death or heart failure event 2. Assess safety by evaluating all system or procedure-related complications 3. Office cuff systolic blood pressure ≥ 140 mmHg and ≤ 180 mmHg, despite being prescribed to at least three antihypertensive medications, including a diuretic 4. Resistant hypertension defined as: Office cuff systolic blood pressure greater than or equal to 160 mmHg and have a diastolic blood pressure greater than or equal to 80 mmHg as well as a 24-hour ambulatory systolic blood pressure greater than or equal to 135 mmHg despite at least one month of maximally tolerated therapy with at least three antihypertensive medications, of which at least one must be a diuretic 5. Serious therapy-related adverse event free-rate through 6 months.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00442286</td>
<td>Rheos® Pivotal Trial</td>
<td>326</td>
<td>A randomized, double-blind, parallel-group trial. All subjects are implanted with the Rheos System. Therapy is programmed OFF for the first month following the implant. Subjects are then randomized 2:1 to receive active therapy for the first six months or have the device turned off for the first 6-month follow-up period. After 6-months, subjects in the OFF arm will have their Rheos system turned on.</td>
<td>1. To demonstrate a clinically significant reduction of office cuff systolic blood pressure at six months. 2. To demonstrate a sustained response to therapy through 12 months. 3. System and procedure related adverse event free rate in the first 30 days. 4. Hypertension-related adverse event and serious device-related adverse event free rate more than 30 days post-implant to 13 months. 5. Serious therapy-related adverse event free-rate through 6 months.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>